Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
Susana Coimbra,1,2 Américo Figueiredo,3 Alice Santos-Silva2,4
1CESPU (Advanced Polytechnic and University Cooperative), Institute of Research and Advanced Training in Health Sciences and Technologies, Gandra-PRD, 2IBMC, Institute for Molecular and Cell Biology, University of Porto, Porto, 3Service of Dermatology, Hospital and University Centre of Coimbra (CHUC), University of Coimbra, Coimbra, 4Biochemistry Laboratory, Biological Sciences Department, Faculty of Pharmacy (FFUP), University of Porto, Porto, Portugal
Abstract: Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.
Keywords: interleukin-17, interleukin-17 receptor, monoclonal antibody, T helper 17 pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]